Sign Up
HR 5463 United States House · 117th Congress

Drug Pricing Transparency and Accountability Act

Summary
Drug Pricing Transparency and Accountability Act This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.
Issues: ✗ HealthcareOpposes HealthcareMoratorium on new non-rural hospitals joining 340B program restricts access to discounted drugs, limiting program expansion and patient affordability.85% confidence
Bill status in committee 1 of 4 stages cleared
Introduction
Sep 2021
Committee Review
Floor Vote
President
Introduced Sep 30, 2021 Last action Oct 1, 2021
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
3
Key actions
0
Committee
2
Oct 1, 2021
Committee
Referred to the Subcommittee on Health.
lower
Sep 30, 2021
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Sep 30, 2021
Introduced
Introduced in House
lower
1 primary · 0 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
Photo of Matthew M. Rosendale, Sr.
Matthew M. Rosendale, Sr.
RRepublican
MT
2